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Abstract 
Background: One objective of the Belgian Rare Diseases plan is to improve patients’ management using phenotypic 
tests and, more specifically, the access to those tests by identifying the biochemical analyses used for rare diseases, 
developing new financing conditions and establishing reference laboratories.
Methods: A feasibility study was performed from May 2015 until August 2016 in order to select the financeable 
biochemical analyses, and, among them, those that should be performed by reference laboratories. This selection was 
based on an inventory of analyses used for rare diseases and a survey addressed to the Belgian laboratories of clinical 
pathology (investigating the annual analytical costs, volumes, turnaround times and the tests unavailable in Belgium 
and outsourced abroad). A proposal of financeable analyses, financing modalities, reference laboratories’ scope and 
budget estimation was developed and submitted to the Belgian healthcare authorities. After its approval in Decem‑
ber 2016, the implementation phase took place from January 2017 until December 2019.
Results: In 2019, new reimbursement conditions have been published for 46 analyses and eighteen reference 
laboratories have been recognized. Collaborations have also been developed with 5 foreign laboratories in order to 
organize the outsourcing and financing of 9 analyses unavailable in Belgium.
Conclusions: In the context of clinical pathology and rare diseases, this initiative enabled to identify unreimbursed 
analyses and to meet the most crucial financial needs. It also contributed to improve patients’ management by estab‑
lishing Belgian reference laboratories and foreign referral laboratories for highly‑specific analyses and a permanent 
surveillance, quality and financing framework for those tests.
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Introduction
In Europe, rare diseases are defined as disorders affect-
ing less than 1 patient in 2.000 individuals [1, 2]. To this 
date, approximately 8.000 rare diseases have been iden-
tified [2–5]. Their diagnosis is often delayed because of 
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the diversity, complexity and rarity of these disorders 
and the lack of access to specialized diagnostic tools [2, 
4–6]. A recent survey of patients with mitochondrial dis-
orders, for example, showed that most of them consult 
five or more clinicians and received at least one incor-
rect diagnosis before the establishment of the final diag-
nosis [7]. In 2009, the Council of the European Union 
published recommendations addressed to the Member 
States in order to encourage them to improve the access 
of patients with rare diseases to high-quality diagnosis, 
care, treatment, social support and information [2, 8, 9].
One of the deliverables of the Belgian action plan for 
rare diseases, published in December 2013, is to improve 
the patients’ diagnosis and follow-up [10]. Because most 
of rare diseases have a genetic origin, the Belgian cent-
ers of human genetics were firstly involved in the process, 
followed by a specific action focused on biochemical lab-
oratory tests performed by medical laboratories. Indeed, 
genetic and biochemical tests are highly complementary 
in order to investigate and follow rare diseases’ mecha-
nisms, the underlying biochemistry, cellular pathways 
and response to treatments [11].
A critical analysis of the Belgian situation in 2015 
identified three factors limiting the patients’ access to 
specialized biochemical laboratory tests: (1) lack of reim-
bursement for a number of specialized tests within the 
framework of the public health system, (2) absence of 
reference laboratories with scientific and technical exper-
tise for complex tests, and (3) need for an official referral 
framework for outsourcing tests unavailable in Belgium 
to foreign laboratories.
To address these shortcomings, the Belgian Institute 
for Health (Sciensano) was mandated by the Belgian 
National Institute for Health and Disability Insurance 
(RIZIV-INAMI) to (1) review the reimbursement of 
biochemical tests prescribed in Belgium in the context 
of rare diseases, and (2) organize the selection, recogni-
tion and financing of Belgian reference laboratories (RLs) 
and foreign referral laboratories for selected biochemical 
tests. A task force was established by Sciensano with clin-
ical pathologists and clinicians.
This paper describes the approach used to identify and 
prioritize the biochemical analyses that should be cov-
ered by the Belgium public health system, either through 
traditional reimbursement of clinical pathology tests or 
through the development of a new system of RLs and for-




In May and June 2015, Sciensano performed a screen-
ing of the European expert centres and medical 
laboratories providing diagnostic tests used in the con-
text of rare diseases published on Orphanet [12], and 
of peer-reviewed scientific publications describing the 
use and validation of biochemical tests used for rare 
diseases.
The inventoried analyses were classified based on 
their respective domains (clinical chemistry, endo-
crinology, haematology, coagulation and hemostasis, 
immunology and non-infectious serology, toxicology, 
therapeutic monitoring) and, when necessary, subclas-
sified according to biological matrices (blood, plasma, 
serum, dry blood spots, urine, urinary stones, feces, 
cerebrospinal fluid, saliva, amniotic fluid) and/or chem-
ical classes of metabolites/proteins (amino acids and 
derivates, pterins, organic acids, steroid acids, purines/
pyrimidines, sugars, lipids and acylcarnitines, porphy-
rins, vitamins, different proteins classes [e.g. transco-
balamines, chemokines, iron-binding blood plasma 
glycoproteins, lectins, (apo-) lipoproteins, immu-
noglobulins, serum free light chains], cytoplasmic 
enzymes, lysosomal enzymes, mitochondrial enzymes, 
inhibitors [e.g. Alfa-1-antitrypsin], regulators [e.g. 
14-3-3 proteins], complement control proteins [e.g. 
Factor H], cofactors [e.g. molybdenum cofactor], and 
other metabolites and components [e.g. α-aminoadipic 
semialdehyde, trimethylamine, sulfites, etc.]). Of note, 
one metabolite assessed in two different matrices, was 
inventoried as two different analyses.
Subsequently, a survey was sent in July 2015 to the Bel-
gian laboratories of clinical pathology performing those 
analyses.
For each test, these laboratories had to provide the fol-
lowing information:
a. The annual number of tests performed;
b. The rare disease(s) for which the test is performed;
c. For analyses not performed in-house, the name 
of the external laboratory to which the analysis is 
outsourced and whether the laboratory wanted to 
develop it in-house by 2020;
d. The average turnaround time (TAT). The TAT was 
defined as the time between the reception of the 
sample by the laboratory and the moment the result 
is reported (in-house or by a foreign laboratory) [13].
The survey was accompanied by a cover letter specify-
ing the context and objectives of the study, and ensuring 
that collected data would be stored and treated in com-
plete confidentiality and anonymity. Participants had 
over two months to complete it and were free to add 
additional tests of clinical pathology if they were not yet 
included in the list. All answers were then collected and 
put together by Sciensano.
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Analyses prioritization
In November 2015, a “Rare Diseases Working Group 
(RDWG)”, composed of clinical pathologists with a 
particular expertise in rare diseases and one Sciensano 
scientific moderator, was set-up by the Belgian Com-
mission on Clinical Pathology.
Between December 2015 until June 2016, the RDWG 
met 2 to 5 times per month in order to discuss the use-
fulness, clinical relevance, limitations and costs of the 
analyses for which information was collected during 
the survey. The goal was to evaluate the feasibility of 
their financing and identify analyses which should be 
prioritized for reimbursement. Particular attention was 
paid to tests for which there was disagreement about 
the clinical utility. The goal was to sort out whether 
discrepancies of opinions were due to evidence-based 
disagreements over the use of the analysis in clinical 
practice or to differences in laboratories’ functioning.
Funding modalities
The INAMI-RIZIV proposed three possible financing 
modalities: (a) nomenclature reimbursement codes, 
(b) recognition and financing of RLs, or (c) financing of 
the outsourcing of analyses unavailable in Belgium to 
foreign laboratories. At the request of Sciensano, the 
RDWG defined for each test the financing modality and 
the total the annual budget that should be allocated to 
each type of financing modality.
In August 2016, Sciensano submitted a proposal of 
priority analyses that should be funded and selection 
criteria for the Belgian RLs to the RIZIV-INAMI. The 
description of each analysis was accompanied by an 
annual budget estimate based on the analytical costs 
and type of financing modality proposed by the RDWG. 
The proposal of priority analyses and required annual 
budget was approved by the INAMI-RIZIV in Decem-
ber 2016.
Implementation phase
The approved proposal was implemented by Sciensano 
and the RDWG from January 2017 until August 2018. 
This consisted of (1) writing the nomenclature reim-
bursement codes (including reimbursement modali-
ties) and publishing them in a Belgian royal decree 
(2) selecting the Belgian RLs, and (3) formalizing offi-
cial collaborations with some foreign laboratories. The 
INAMI-RIZIV evaluated this proposal from October 
2018 until December 2019.
Statistical analyses
One-way analysis of variance (ANOVA) was made with 
GraphPad Prism 8.2.0 (GraphPad Software, San Diego, 
CA).
Results
Figure 1 illustrates the study outline.
Analyses inventory
Unreimbursed analyses of clinical pathology used in 
the context of rare diseases were identified based on the 
literature search and survey that was sent to the 17 Bel-
gian laboratories of clinical pathology performing these 
analyses (8 university laboratories and 9 non-university 
laboratories).
Survey results
All laboratories completed the survey. When necessary, 
they added analyses that they perform and that were 
not included in the initial survey. The survey enabled 
Sciensano to identify 483 analyses of clinical pathology 
used in the context of rare diseases. Of these tests, 163 
(34%) were unreimbursed in July 2015 and, therefore 
covered by the Belgian public healthcare system. In this 
case, the patient’s personal share varied between 0 and 
20 euros per laboratory test request.
Selection of priority analyses
Among the unreimbursed analyses, the RDWG selected 
priority tests based on the survey answers and, more 
specifically, on (1) the lack of existing reimbursed tests 
in the Belgian nomenclature for a rare disorder, (2) 
the absence of existing proposals for reimbursement 
already submitted to the Belgian healthcare authori-
ties, (3) the clinical utility of the test (showing higher 
medical and/or analytical benefits compared to other 
existing techniques; some obsolete tests were replaced 
as part of the exercise), (4) the high specificity of the 
analyses for rare diseases (analyses widely performed in 
other contexts than the diagnosis or follow-up of rare 
diseases patients, were not included in the list of prior-
ity analyses).
Using those criteria, 73 priority analyses were 
selected for coverage in the following fields: clini-
cal chemistry (46), coagulation and hemostasis (11), 
immuno-haematology and non-infectious serology 
(9), hormonology (4), and haematology (3) (cf. Fig.  2). 
Among them, 64 analyses were performed in Belgium 
and 9 outsourced abroad. Moreover, 62 of the 64 analy-
ses performed in Belgium (97%) were only performed 
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in university hospital laboratories. A great disparity 
was observed among the annual volumes (from 1 to 
more than 5000 tests per year), as well as TAT (ranging 
from 40 h up to 2 months).
Definition of financing modalities
Table 1 summarizes the characteristics of the three types 
of financing modalities.
For analyses performed in Belgium, the choice of 
developing a reimbursement nomenclature code versus 
Fig. 1 Illustration of the different steps of the study. BCCP Belgian Commission on Clinical Pathology, INAMI-RIZIV National Institute for Health and 
Disability Insurance, RD Royal Decree, RDWG Rare Diseases Working Group, RLs Reference laboratories
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selecting a Belgian reference laboratory (RL) was based 
on the degree of centralization of the performance of 
the test (performed by a limited versus larger number of 
laboratories) and the required level of medico-scientific 
expertise and/or specialized infrastructure.
The development of nomenclature codes or modifica-
tion of existing codes was favored for analyses performed 
by at least 3 Belgian laboratories for clinical pathology. 
The selection of RLs on the other hand was preferred for 
analyses characterized by a low annual volume, requir-
ing specific infrastructure and/or scientific expertise, and 
performed by 1 to 3 Belgian laboratories (cf. Fig. 3a, b). 
Finally, the development of formal collaborations with 
foreign laboratories was proposed to cover analytical and 
shipment costs for low volume analyses unavailable in 
Belgium and thereby outsourced abroad.
Development of reimbursement nomenclature codes
The Belgian reimbursement system for laboratory tests 
combines a fee for service per test and a flat rate which 
varies in function of the tests requested. The INAMI-
RIZIV is responsible for establishing the flat rates, reim-
bursement fee per test and reimbursement rules for test 
(e.g. maximum one per year, only reimbursed in patients 
with a specific disorder, etc.), as well as for organizing, 
managing and supervising its correct application [14–16].
A reimbursement code for a clinical pathology test con-
tains the (1) name of the test including possible additional 
technical requirements, (2) domain of clinical pathology 
to which the test belongs, (3) biological matrix, (4) theo-
retical reimbursement tariff represented by a ‘B-value’, (5) 
maximal frequency of reimbursement (e.g. maximum 1 
test/day) and, if applicable, (6) diagnostic and/or cumu-
lation rules. Of note, the theoretical tariff is calculated 
by multiplying the analysis’ B-value by the B-coefficient 
which is regularly adapted by the INAMI-RIZIV (current 
Fig. 2 Repartition of the selected financeable priority analyses 
among their respective domains of clinical pathology
Table 1 Financing modalities characteristics
BCCP Belgian Commission on Clinical Pathology, INAMI-RIZIV National Institute for Health and Disability Insurance, RDWG Rare Diseases Working Group, RLs reference 
laboratories
Financing modalities Nomenclature reimbursment 
codes
Reference laboratories (RLs) Conventions with foreign 
laboratories
Type of medical analyses Analyses of clinical pathology
Analyses’ availability Available in Belgium Not available in Belgium
Annual volume High Moderate to low Low
Laboratories who can benefit from 
the financing
All Belgian laboratories of clinical 
pathology
Only Belgian laboratories of 
clinical pathology recognized 
as RLs
Specific foreign laboratories of clinical 
pathology
Laboratories’ selection procedure None Belgian call for application
By Sciensano
Every 5 years
By the RDWG of the BCCP and 
Sciensano
Every year






Financing source INAMI‑RIZIV (through a budget envelop specifically dedicated to the Action 1 of the Belgian plan for rare 
diseases)
Follow‑up of laboratories’ activities 
and quality of the analyses
By the RDWG of the BCCP and Sciensano
Annual evaluation of the necessary 
budget
By Sciensano and the INAMI‑RIZIV Insurance Committee
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value: B = 0032012 since 01/01/2020 [17]). For instance, 
a B-value of 1000 corresponds to a theoretical tariff of 
approximately 32€ (including reagents/materials, per-
sonnel, quality controls costs). The fee of service and flat 
rate are calculated based on the theoretical tariffs of the 
requested tests.
Diagnostic rules give an accurate description of the 
context in which the test can be reimbursed (e.g. specific 
patient population, clinical symptoms) while cumula-
tion rules define which tests cannot be combined for 
reimbursement.
The costs of the medical services (including medical 
laboratory analyses) that are not included in the Bel-
gian reimbursement system are invoiced to the patients. 
By contrast, 25% of the costs of medical services with a 
nomenclature code are reimbursed by the INAMI-RIZIV. 
The rest is mainly charged to the health insurance of the 
patient. In some cases (not applicable to patients with 
chronic diseases), the patient pays a small amount that 
represents the difference between the cost of the medical 
service and the interventions of the INAMI-RIZIV and 
health insurance.
Between March and July 2016, the RDWG proposed 
nomenclature codes for all the priority tests selected for 
a reimbursement. Based on the B-values and number of 
tests performed reported in the survey, the total annual 
budget was calculated and submitted in August 2016 to 
the INAMI-RIZIV. After the budget approval, diagnostic 
and cumulation rules were developed by the RDWG 
between January and June 2017. The proposal for new 
reimbursement codes was approved by the Belgian Com-
mission on Clinical Pathology in September 2017 and 
submitted to the INAMI-RIZIV in October 2017. After 
evaluation and approval by different INAMI-RIZIV and 
external bodies (i.e. Technical Medical Council, Insur-
ance Committee, national medical-mutualistic commis-
sion), a royal decree project was prepared and submitted 
to the Belgian Budget ministry and Healthcare and Social 
Affairs ministry. The royal decree formalizing the modifi-
cation of 4 existing nomenclature reimbursement codes 
and the creation of 42 new codes was published on 3 
February 2019 and came into effect on 1 April 2019 [18]. 
Table  2 contains the list of the 42 new nomenclature 
codes.
Selection of the reference laboratories (RLs)
The selection criteria for the Belgian RLs are summa-
rized in Table 3. Special attention was paid to the labora-
tories’ quality management system, its medico-scientific 
expertise (including the extent of its collaborations with 
external rare diseases experts), the education program 
addressed to the laboratory staff and medical prescribers, 
and whether the laboratory will be able to offer the test 
during at least 5 years.
The call for application was prepared by Sciensano 
between January and June 2017 and included:
Fig. 3 Volumes reported in 2016 for the 73 priority analyses categorized according to their financing modality
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Table 2 List of the 42 new reimbursement nomenclature codes [18]
Domains of clinical pathology Biological matrices Names of the nomenclature codes
Clinical chemistry Blood Separated identification and assessment of C22–C26 fatty acids, phytanic acid and pristanic 
acid by mass spectrometry
Methylmalonic acid and succinylacetone assessment
Pipecolic acid assessment
Guanidinoacetate and creatine assessment
Measurement of alpha‑d‑galactose 1‑phosphate (Gal‑1‑P) in erythrocytes
Separated assessment of cholestanol, 7‑dehydrocholesterol and 8‑dehydrocholesterol
Separated assessment of desmosterol, lathosterol, campesterol, sitosterol and 27‑hydroxycho‑
lesterol
Identification of asialotransferrin, monosialotransferrin, and asialotransferrin
Determination of the Alpha‑1‑proteinase inhibitor (= alpha‑1‑antitrypsin) phenotype
Serum/plasma Organic acids assessment
Urine Guanidinoacetate and creatine assessment
Separated assessment of polyols after fractionation
Separated assessment of mono‑ and disaccharides after fractionation
Separated assessment of polyols, monosaccharides and disaccharides after fractionation
Cerebrospinal fluid Specific mass spectrometric identification and dosage of organic acids
Specific assessment of amino acids by LC–MS/MS after derivatization and fractionation
Guanidinoacetate and creatine assessment
Stool Measurement of pancreatic Elastase 1
Amniotic fluid Separated assessment of 7‑dehydrocholesterol and 8‑dehydrocholesterol





Haematology Blood Eosin‑5′‑maleimide (EMA) binding test
Coagulation and hemostasis Plasma Alpha 2‑Antiplasmin measurement
Functional analysis of von Willebrand factor‑cleaving protease (ADAMTS13)
Identification of the von Willebrand factor‐cleaving protease inhibitor
Diagnosis of type 2N von Willebrand disease
von Willebrand factor collagen‑binding activity assay
von Willebrand factor multimer analysis
von Willebrand factor propeptide assay
Detection of heparin‑induced antibodies (= diagnosis of heparin induced thrombocytopenia 
[HIT])
Functional analysis of HIT antibodies
Platelet secretion assay




Serum Detection of anti‑podocytes antibodies in the context of membranous glomerulonephritis 
diagnosis
Detection of anti‑podocytes antibodies in the context of membranous glomerulonephritis 
follow‑up
Determination of anti‑acetylcholine receptor antibodies
Immunoassay identification of autoantibodies against bullous pemphigoid (BP) antigen 180, 
BP230 (bullous pemphigoid antigen 1), DSG1 (desmoglein 1), DSG3 (desmoglein 3), type VII 
collagen and envoplakin
Follow‑up of the production of autoantibodies against bullous pemphigoid (BP) antigen 180, 
BP230 (bullous pemphigoid antigen 1), DSG1 (desmoglein 1), DSG3 (desmoglein 3), type VII 
collagen and envoplakin by immunoassay
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Table 3 Illegibility criteria for the selection of the Belgian Reference laboratories
Main aspects Criteria to be met Evaluation procedure
Localisation, structure, organization and governance Applicants are laboratories of clinical pathology located in Belgium 
and certified according to the Royal Decree of 3 December 1999 
[19]
Applicants provide the full contact details of the laboratory, its direc‑
tor, quality coordinator and of the clinical pathologist(s) responsi‑
ble for the performance of the analysis for which they apply
Applications in the form of a consortium have to be justified
A clear description of the tasks performed by each laboratory com‑
posing the consortium must be provided
Documentation audit
On‑site visits for RL 
in the form of a 
consortium
Quality Applicants have to join the following documents to the application 
file:
 Full content of the laboratory quality manual
 Description of the method and equipment used to perform the 
analysis (Standard Operating Procedure)
 Analysis validation file (including the reference values and biblio‑
graphic references used to validate the method and interpret 
analytical results)
 Description of the External Quality Assessment programs and/or 
ring tests related to the analysis for which they apply and to which 
they participate




Reporting of analytical results and communication skills Applicants have to specify:
 The units used to report the results and if those units are SI units or 
not (if not, they also have to mention the reason)
 Their mean turnaround time (TAT)a for the analysis for which they 
apply (expressed in days, with a standard deviation if desired)
 The link to their website where the prescribers can find the analyti‑
cal TAT 
 If they undertake to respect the TAT mentioned on their website/
prescription forms
 If they undertake to be more flexible and reduce their TAT for 
urgent analyzes in order to guarantee the good management of 
the patient
 If they are able to report the results in at least one of the Belgian 
national languages and in English
 If they accept to publish the prescription forms in French, Dutch 
and English on their website
 If they accept that information related to their activities (no patients 
details/personal information) will be used to update and enrich 
the Belgian rare diseases registries
Documentation audit
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1. an introductory letter explaining the call’s context 
and objectives;
2. an explanatory document describing the applicants’ 
profile, RLs missions, application documents, selec-
tion procedure, and analyses for which applicants 
could apply for a recognition of expertise;
3. the application documents that must be completed 
in English (application form and agreement forms for 
the submission of the application signed by the labo-
ratory director and clinical pathologist responsible 
for the performance of the test);
4. French and Dutch translations of the application 
documents provided to ensure an optimal compre-
hension of the application documents written in Eng-
lish.
The call for application was officially opened on 1 
July 2017. The laboratories had five months to apply 
for one or several analyses. Moreover, the laboratories 
were free to apply together in the form of a consor-
tium. In this case, the relevance of the consortium had 
to be justified in the application form.
The evaluation procedure took place between Decem-
ber 2017 and April 2018. All applications were reviewed 
by three independent experts (not linked to the Belgian 
laboratories of clinical pathology). This was performed 
through documentation audits of the application form, 
laboratory quality manual, accreditation certificate, 
validation file and standard operating procedure (SOP) 
for the performance of the analysis, peer-reviewed pub-
lications illustrating the laboratory scientific expertise 
and collaborations, guidelines, decision algorithms for 
the diagnosis/follow-up of rare diseases or education 
material developed by the laboratory). If necessary, 
additional on-sites visits were performed in March and 
April 2018 by Sciensano in order to assess practical 
aspects of the analysis’ validation and SOP.
RL reference laboratory, SI International System of Units, TAT Turnaround Time
a For analyses made in Belgium, the TAT corresponds to the time period between the reception of the sample by the laboratory and the moment at which the 
clinician receives the validated results; for analyses outsourced abroad, it corresponds to the time period between the test prescription and the moment at which this 
clinician receives the validated results
Table 3 (continued)
Main aspects Criteria to be met Evaluation procedure
Scientific and medical expertise Applicants have to provide:
 Their annual volume of tests during the 5 last years for the analysis 
for which they apply
 Their list of scientific communications (peer‑reviewed publications, 
posters, etc.) related to rare diseases management
 A short description of their projects in the domain of clinical pathol‑
ogy to which the analysis for whom they apply belongs (basic 
research projects, clinical research, epidemiological research, 
validation of new methods, acquisition of new equipment, etc.)
 Their affiliations to international (reference) networks with a short 
description of the (1) network spectrum of activities, (2) applicants 
duties/activities within the network, and (iii) frequency of appli‑
cants’ meetings/exchanges of information with other network 
members
 The names of the databases in which analytical results are recorded 
(patient’s medical record, laboratory database, Regional/national 
database, network database, etc.)
 A description of their participation to multidisciplinary meetings 
(frequency, medical disciplines [specializations] of the experts who 
attended the meetings, aspects discussed during the meetings 
[clinical cases, analytical results interpretation, communication 
between the laboratory and prescribers, development of guide‑
lines/healthcare algorithms, etc.])
 A description of the diagnosis and/or follow‑up guidelines/algo‑
rithms that they may develop for some rare diseases
 A description of the training programs that they develop and of the 
targeted audience
Documentation audit
Activities sustainaibility Candidates undertake to carry out the analysis for which they apply 
for at least 5 years in the case of a recognition as RL and confirm 
that they possess the necessary qualified personnel, equipment 
and infrastructure to carry out the analysis during this period of 
time
Documentation audit
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Fig. 4 Representation of the new Belgian reference laboratories. AADC aromatic l‑amino acid decarboxylase, BH4 tetrahydrobiopterin, CSF 
cerebrospinal fluid, DHFR dihydrofolate reductase, DHPR dihydropteridine reductase, FOLR1 folate receptor 1, MTHFR methylene tetrahydrofolate 
reductase, PA pyridoxic acid, PL pyridoxal, PLP pyridoxal‑phosphate, PM pyridoxamine, PN pyridoxine, RCDP rhizomelic chondrodysplasia punctate, 
SCID severe combined immunodeficiency, SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
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Reference laboratories recognition
Among the 18 analyses included in the call for applica-
tion scope, RLs were recognized on 3 December 2019 
for 16 analyses. The names of the institutions to which 
RLs belong, the names of the analyses for which they 
have been recognized and the main clinical indications 
of these tests, as well as RLs localization are illustrated 
in Fig.  4. All of them were Belgian university hospi-
tal laboratories which participate to External Quality 
Assessment schemes [EQAs] for 6 of the 16 analyses 
considered, international ring tests for 9 analyses, and 
a combination of both for 1 analysis). No applications 
were submitted for two analyses included in the call: 
assessment of the acid-labile subunit in serum and 
detection of the 14-3-3 protein in the cerebrospinal 
fluid.
RLs were set up in the form of a consortium of 
two laboratories for two analyses, namely for (1) 
the assessment of α-aminoadipic semialdehyde in 
urine and δ1-piperideine-6-carboxylate in plasma 
and urine (mainly used in the case of pyridoxine-
dependent seizures), and (2) the assessment of pter-
ins in urine and of the 6,7-dihydropteridine reductase 
activity in dry blood spots (used in the context of 
hyperphenylalaninemia).
For two other analyses (spectrofluorimetric assess-
ment of plasma porphyrins and assessment of free 
erythrocyte protoporphyrins), two RLs have been rec-
ognized instead of one because of their similar quality, 
annual volume and long-term expertise recognized at 
the international level (membership to the European 
Porphyria Network for more than 10 years).
Prescription forms and criteria, as well as instruc-
tions for the sampling, storage and transport of the 
samples, have been developed for each RL.
The call for application for the Belgian RLs should be 
renewed every 5 years in order to allow modifications 
of the Belgian RLs scope based on adaptations of the 
activities of the Belgian laboratories of clinical pathol-
ogy and tests’ availability in Belgium.
Collaborations with foreign laboratories
After the evaluation of the quality, expertise and costs 
of different European laboratories performing the pri-
ority analyses that are unavailable in Belgium, part-
nerships have been developed with 5 foreign partners 
for the outsourcing of 9 analyses (cf. Fig. 5). The effi-
ciency, and quality of analyses outsourced abroad, as 
well as the needs of collaborations’ renewal based on 
the evolution of the tests availability in Belgium, will 
be annually reviewed by the RDWG.
Impact of the project on the management of the patients 
with rare diseases
The implementation of new reimbursement conditions 
for a large number of analyses has improved the patients’ 
access to specialized diagnostic tests. Indeed, these anal-
yses were previously performed for free by the Belgian 
medical laboratories or charged to the patients. Since 
the entry into force of the 42 new reimbursement codes, 
the laboratories are paid for the performance of these 
tests and the costs are no longer charged to the patients. 
Thus, between 1 April and 31 December, 2019, 8.599 
tests could be reimbursed under the 42 new nomencla-
ture codes. This represents a saving of €282.029,84 for the 
patients with rare diseases and Belgian medical laborato-
ries in a nine-months period. The related expenditures of 
the INAMI-RIZIV had amounted to €70.507,46 (average: 
€7834,16 per month). The remainder (€211.522,38) had 
been charged to the health insurances of the patients.
Besides, the selection of RLs has mainly helped to 
improve the management of the patients with rare dis-
eases by increasing the availability of some highly-spe-
cialized tests in Belgium and by establishing a control 
and follow-up framework for the RLs activities. In that 
respect, some analyses that were not available in Belgium 
before this study (i.e. the assessments of the dihydropteri-
dine reductase activity in dried blood spots, B6 vitamers 
in plasma, pterins in urine, α-aminoadipic semialdehyde 
and δ1-piperideine-6-carboxylate in urine) have been 
developed by some Belgian university laboratories of 
clinical pathology after the presentation of the results of 
the feasibility study in 2016.
Concerning the quality of the tests, this project also 
enabled to rationalize the outsourcing and performance 
of rare analyses. Before 2016, some medical analyses cov-
ered by this project were heterogeneously outsourced to 
several Belgian or foreign laboratories, even if available 
in Belgium. This happened without any harmonization 
of the outsourcing procedure or possible control and fol-
low-up of the volumes, quality, TAT, or costs of the tests 
by the Belgian healthcare authorities. In that respect, the 
recognition of Belgian RLs in 2019 enabled to centralize 
the performance of some analyses within one Belgian 
RL versus 5 (assessment of pterins in urine), 3 (assess-
ment of 5-methyltetrahydrofolate in cerebrospinal fluid) 
or 2 (assessments of plasmalogen levels in erythrocytes, 
and α-aminoadipic semialdehyde and δ1-piperideine-
6-carboxylate in urine) different medical laboratories in 
2015. This has had a positive impact on patients’ manage-
ment through the possible reduction of the TAT, and a 
better tracing of the samples and follow-up of the quality 
of the analyses.
Finally, the project also helped to reduce patients’ costs 
for analyses that are not available in Belgium. Since 1 
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Fig. 5 Foreign laboratories with whom collaborations were established for the outsourcing of analyses unavailable in Belgium. CSF cerebrospinal 
fluid
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January 2019, the shipment and analytical costs of the 
outsourced analyses are reimbursed through a specific 
financial envelop allocated by the INAMI-RIZIV.
Impact of the project on the Belgian RLs’ cost‑effectiveness
This project also had a positive impact on the Belgian 
RLs cost-effectiveness. Indeed, before the official RLs 
recognition on 3 December 2019, the costs of the medi-
cal analyses performed by these laboratories were not 
or only partially invoiced to the patients. This situation 
induced insufficient incomes for the laboratories that 
performed these tests. The RLs recognition and funding 
by the Belgian healthcare authorities helped to deal with 
this problem. The RLs are receiving a reimbursement 
for the analyses performed since the 1 January 2019. 
Moreover, since 2019, RLs’ costs related to their annual 
participation to quality controls and accreditation of the 
analyses for which they have been recognized are totally 
reimbursed. This is achieved through a specific annual 
envelop (€135.000 in 2019 and 2020) allocated by the 
INAMI-RIZIV.
The proposal of centralization of some analyses within 
one Belgian RL formulated after the feasibility study 
(2016) also helped to increase the Belgian laboratories’ 
annual volumes of tests for those analyses, with a positive 
effect on the amortization of their equipment purchase 
Fig. 6 Significant impact of the feasibility study results on the annual volumes of six analyses. Comparison of the volumes of tests reported by the 
Belgian laboratories of clinical pathology for 6 different years: group A (light grey bars, period before the presentation of the results of the feasibility 
study [data collected for 2014 and 2015]) versus group B (dark grey bars, period after the presentation of the results of the feasibility study [data 
collected for 2016 and 2017]) versus group C (black bars, period from RLs’ recognition [data collected for 2019 and 2020]). Values were calculated 
as mean volumes ± SD, n = 2 for the 3 groups (A,B,C) of two successive years. Statistical analyses were performed by one‑way ANOVA with Tukey’s 
posttest for multiple comparisons between the 3 groups. Asterisks indicate values that are statistically significantly different from each other 
(*p < 0.05). Analyses presented in each panel: a assessment of α‑aminoadipic semialdehyde and δ1‑piperideine‑6‑carboxylate in urine; b assessment 
of B6 vitamers in plasma; c assessment of pterins in urine; d assessment of Complement component Factor B; e assessment of Complement 
component Factor Bb; f assessment of intra‑leukocyte cystine. RLs Reference laboratories
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costs, analyses’ validation costs and staff training costs. 
Figure  6 illustrates the comparison of the mean annual 
volumes collected for three different periods: before the 
presentation of the results of the feasibility study (group 
A, data collected for 2014 and 2015), after the presenta-
tion of the results of the feasibility study (group B, data 
collected for 2016 and 2017), and after the RLs’ recogni-
tion (group C, data collected for 2019 and 2020). Results 
are expressed as mean volumes ± SD for 2 successive 
years (n = 2). For the 6 analyses shown in this figure, a 
significant increase (p < 0.05) of the mean annual volumes 
of tests could be observed after the presentation of the 
results of the feasibility study in 2016. This highlights 
the positive impact of this project on the development 
of new analyses in Belgium (panels a–c) but also on the 
performance of some other analyses available in Belgium 
since many years (panels d–f). For the other analyses per-
formed by RLs, no statistically significant modification 
of the annual volumes could be observed between 2014 
and 2020 (see Additional file 1: Figure S1). This may be 
explained by the very low prevalence of the diseases for 
which these analyses are prescribed and therefore the 
limited number of tests that makes the inter-groups dif-
ferences less important.
Follow‑up of costs and expertise recognition
An annual activity and financial report describing the 
activities, financing and renewal of the Belgian RLs 
of clinical pathology and the outsourcing of analy-
ses to foreign laboratories will be annually sent to the 
INAMI-RIZIV.
Discussion
This study is the first Belgian initiative for the improve-
ment of the management of patients with rare diseases 
through the promotion and financing of analyses of clini-
cal pathology.
Its approach derives from the “RAND/UCLA appropri-
ateness method”, which aims to measure and validate the 
necessity and usefulness of clinical procedures based on 
the consensus of experts’ opinions [21, 22].
Several inputs of this project are worth mention-
ing. First of all, this study enabled to create a perma-
nent working group composed of Belgian experts in 
rare diseases management within the Belgian Com-
mission on Clinical Pathology. This will help to per-
form a continuous follow-up of rare diseases diagnosis 
and epidemiology in Belgium and of the efficiency and 
quality of medical analyses performed in these particu-
lar contexts. Moreover, the collaboration between this 
working group and Sciensano enabled the (1) identifi-
cation of unmet financing needs for specific analyses 
of clinical pathology used for rare diseases’ diagnosis/
follow-up, (2) set-up of coverage of these tests by the 
Belgian Healthcare system, under the surveillance of 
Sciensano and INAMI-RIZIV, and (3) establishment of 
reference laboratories (RLs) for the most specific tests.
The establishment by the Belgian healthcare authori-
ties of a specific budgetary envelop dedicated to anal-
yses of clinical pathology supports the usefulness of 
these tests in the context of rare diseases diagnosis and 
follow-up in parallel with genetic tests.
Nowadays, RLs have been recognized for a few types 
of medical analyses and in a limited number of coun-
tries. Most of them are focused on human genetics and 
microbiology tests [23–25]. The establishment of Bel-
gian RLs for some analyses used in the context of rare 
diseases performed during this study echoes the pre-
vious recognition of Belgian National Reference Cent-
ers for human microbiology in 2011 [24] and is to our 
knowledge the first RL initiative in the context of rare 
diseases and for analyses of clinical chemistry, haema-
tology and immunology.
The RLs recognition offers several advantages in terms 
of healthcare quality. First, it took place after a harmo-
nized selection procedure for all tests considered. Sec-
ond, affiliations of RLs to university hospitals improves 
the clinical management of the patients with rare dis-
eases due to the close link between clinical and labora-
tory activities and reduced TAT. Third, RLs possess a 
highly-specialized equipment and perform the analyses 
using validated methods based on peer-reviewed publi-
cations and international guidelines. Fourth, RLs annu-
ally participate to external quality controls for the test(s) 
for which their expertise has been recognized. Fifth, the 
centralization of highly-specific tests to one or two RL(s) 
is cost-effective regarding the amortization of laboratory 
costs related to the performance of small tests’ annual 
volumes, as it is the case for rare diseases, and helps the 
prescribers to rapidly identify the RLs to which clinical 
samples have to be sent. Finally, RLs recognition and 
financing will also encourage the Belgian laboratories to 
develop and validate new tests that remain unavailable in 
Belgium.
In addition, the selection of RLs will have a positive 
impact on public health by offering useful expertise in 
rare diseases management to the medical authorities, 
healthcare professionals and patients and by helping 
to collect information about rare diseases in Belgium 
through national databases and registries.
Lastly, it is important to mention that recognition 
of RLs by the Belgian healthcare authorities gives the 
laboratory a particular visibility and notoriety at the 
national and international levels, and a responsibility in 
terms of healthcare excellence and scientific expertise. 
This helps RLs to expand their collaborations and to 
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position themselves within the Rare Diseases European 
Reference Networks [26].
Conclusions
This initiative of the Belgian plan for rare diseases (1) 
promotes healthcare quality and the expertise recogni-
tion and collaborations of Belgian rare diseases experts 
at the national and international levels, (2) offers a bet-
ter financing to the laboratories of clinical pathology 
performing highly-specific analyses in the context of 
rare diseases, and (3) enables to reduces patients’ costs.
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